News

Combination Regimen vs Docetaxel in Advanced NSCLC

10-Year Update on Proton vs Photon Radiotherapy for Locally Advanced NSCLC

Perioperative Use of Ivonescimab in Resectable NSCLC

FDA Approves Tumor Treating Fields Therapy for Metastatic NSCLC

Exploring Comprehensive Biomarker Testing in Patients With NSCLC

Insights on Concomitant Driver Alterations in EGFR-Mutated NSCLC

ASTRO 2024: Combination of High-Dose Radiotherapy and Immunotherapy for Metastatic NSCLC

Novel Monoclonal Antibody Under Study in Phase III Trial of Nonsquamous NSCLC

ASTRO 2024: Can SBRT to the Primary Tumor Site Improve Outcomes in Metastatic NSCLC?

ESMO 2024: Targeting an Intestinal Bacterium to Improve Outcomes With Immunotherapy in NSCLC

ASTRO 2024: Role of Durvalumab With Radiotherapy for Some With Locally Advanced NSCLC

Neoadjuvant/Adjuvant Nivolumab With Chemotherapy Approved for Resectable NSCLC

Can Tusamitamab Ravtansine Improve Survival in CEACAM5-High NSCLC?

ASCO Quality 2024: Upfront Liquid Biopsy May Guide Therapeutic Options in NSCLC

ASCO Quality 2024: Can the Expansion of Medicaid Improve Clinical Outcomes in NSCLC?

ESMO 2024: Novel EGFR TKI After Amivantamab Therapy for Lung Cancer With EGFR Mutation

Osimertinib Approved for Treatment of Stage III NSCLC After Chemoradiotherapy

WCLC 2024: Adding JAK1 Inhibitor to Pembrolizumab in Metastatic PD-L1–Positive NSCLC

WCLC 2024: Novel Tyrosine Kinase Inhibitor vs Gefitinib in EGFR-Mutated NSCLC

Amivantamab Plus Chemotherapy Approved by FDA for NSCLC With Certain Genetic Mutations

WCLC 2024: Survival Update From TROPION-Lung01 on Dato-DXd vs Docetaxel in NSCLC

ESMO 2024: Update on Encorafenib Plus Binimetinib in BRAF V600E–Mutated NSCLC

ESMO 2024: Can Adding Corticosteroid to Radiotherapy for NSCLC Reduce Pneumonitis?

WCLC 2024: Ivonescimab vs Pembrolizumab in First-Line Treatment of PD-L1–Positive NSCLC

WCLC 2024: DUBLIN-3 Update on Plinabulin Plus Docetaxel in NSCLC

Molecular Mutations in NSCLC With Brain Metastases: Impact on Survival

WCLC 2024: Immunotherapy Before and After Surgery for NSCLC

WCLC 2024: AEGEAN Trial Update on Perioperative Durvalumab in Resectable NSCLC

LIBRETTO-431: East Asian Subgroup Analysis of Selpercatinib in RET-Positive NSCLC

Novel Triplet Under Study for Metastatic NSCLC: Early Phase II Results

Advanced NSCLC With MET Exon 14 Skipping Mutation: Focus on Novel MET Inhibitor

End-of-Life Care in Lung Cancer: Systemic Therapy Variability Among Oncologists

Atezolizumab Before and After Chemoradiation: Novel Plan for Unresectable Stage III NSCLC

NSCLC in Patients Older Than Age 75: Risks and Benefits of Surgery

Lung Cancer Screening in Low-Risk Individuals: More Harm Than Good?

Chemotherapy-Free Combination Approved by FDA for EGFR-Mutated NSCLC

How Intratumoral Bacteria Might Improve Outcomes With Immunotherapy for NSCLC

FDA Approves Use of Durvalumab With Chemotherapy Before and After Surgery in NSCLC

Is Immune Checkpoint Inhibition of Benefit in BRAF-Positive NSCLC?

Researchers Explore the Impact of Geographic Accessibility on Lung Cancer Screening

Is a Fixed 2-Year Duration of Pembrolizumab Treatment Safe in Advanced NSCLC?

FDA Investigates Repurposing a Diabetes Drug to Overcome Chemoresistance in NSCLC

Does E-Cigarette Use Impact Lung Cancer Screening Uptake?

Bispecific Antibody Plus EGFR Inhibitor in EGFR-Mutant Lung Cancer

EGFR-Mutated NSCLC: MRD Detection and Adjuvant Osimertinib

Refining Treatment of Oligometastatic NSCLC Is a Work in Progress

University of Utah Researchers Receive $2.6 Million Grant to Study Lung Tumor Biomechanics

Quality-of-Life Data Support Pembrolizumab’s Role in Early-Stage NSCLC

Use of Icotinib After Adjuvant Chemotherapy in EGFR-Mutated NSCLC

Health-Related Quality-of-Life Data From ALINA on Alectinib in NSCLC

Geriatric Assessment: Determining Optimal Treatment for Older Patients With NSCLC

Patient Education Initiative for Veterans With Non–Small Cell Lung Cancer

Bilobectomy vs Middle Lobe–Sparing Sleeve Resection for Central NSCLC of the Right Lower Lobe

Amivantamab Plus Lazertinib in High-Risk Subgroups With Advanced NSCLC

ASCO 2024: Study Analysis Focuses on Nodal Status With Neoadjuvant Nivolumab in Stage III NSCLC

ASCO 2024: Tumor-Treating Fields Therapy for Patients With NSCLC and Brain Metastases

Patient-Reported Outcomes: Wedge Resection vs Uniportal Thoracoscopic Segmentectomy for Peripheral NSCLC

ASCO 2024: New Antibody-Drug Conjugate Under Study in First Line for Advanced NSCLC

ASCO 2024: Air Pollution, Gene-Environment Interactions, and Risk of NSCLC in Nonsmokers

ASCO 2024: Novel KRAS G12C Inhibitor Plus Pembrolizumab for Advanced, Mutant NSCLC

ASCO 2024: CodeBreaK 101 Update on Sotorasib Plus Chemotherapy for Advanced NSCLC

ASCO 2024: Updated IMpower010 Survival Analysis of Atezolizumab in PD-L1–Positive NSCLC

ASCO 2024: Adagrasib vs Docetaxel in KRAS G12C–Mutated NSCLC

ASCO 2024: Subcutaneous vs Intravenous Amivantamab Combined With Lazertinib in NSCLC

ASCO 2024: Early Results From EVOKE-01 of Sacituzumab Govitecan in Metastatic NSCLC

ASCO 2024: Is Telehealth-Based Early Palliative Care Feasible in Advanced NSCLC?

ASCO 2024: Osimertinib After Chemoradiotherapy for EGFR-Mutated NSCLC

ASCO 2024: Long-Term Outcomes With Lorlatinib vs Crizotinib in ALK-Positive NSCLC

Adding Perioperative Nivolumab to Neoadjuvant Chemotherapy for Resectable NSCLC

STK11 Mutations and Immunotherapeutic Efficacy in NSCLC

Case Study: Pathologic Complete Response After Triple-Induction Therapy for NSCLC

Insights Into NSCLC Management: Comprehensive Study Findings From South Korea

Can Oligoprogressive NSCLC Be Treated With Radiotherapy After Immunotherapy?

Does Thoracic Radiotherapy Induce Changes in Cardiac Morphology and Function?

Can Novel Methylation Biomarkers Enhance Lung Cancer Diagnosis via Bronchial Washing Samples?

ASCO Plenary Series: Phase II Study of Glecirasib in KRAS G12C–Mutated NSCLC

Molecular and Radiographic Biomarkers of Lung Cancer in Never-Smokers